An anti–PD-1 monoclonal antibody formerly known as BMS-936558 (PMID 23714523). Approximate rate of pneumonitis is circa 3%, of which 1% are severe. Incidence of pneumonitis is higher in those patients on concomitant nivolumab plus ipilumab (PMID 25891304)

Last update : 22/10/2017
I - Interstitial/parenchymal lung disease
II - Pulmonary edema - ARDS - Acute lung injury
III - Pulmonary and/or alveolar hemorrhage
IV - Airway involvement
V - Pleural and/or pericardial involvement
IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
X - Systemic conditions, syndromes and reactions
XII - Cardiovascular involvement / toxicity
XV - Pulmonary pathology
XVI - Imaging
XVII - Infections & related conditions